LLY4841184 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the LLY4841184 bond issued by Elanco Animal Health, Inc. It outlines key facts such as the issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes information on the bond's interest payments, showing a semi-annual fixed rate coupon of 6.40%, and details its redemption schedule.
Deferring cash fees, Elanco (ELAN) director Kapila K. Anand acquires 642 stock-linked units.
Elanco Animal Health Inc. director Kapila K. Anand acquired 642.0277 deferred stock units on September 30, 2026, by deferring her cash retainer fees. Each unit is equivalent to one common share, and her total holdings after the transaction reached 10,721.5916 deferred stock units. The units will be settled in stock upon her separation from the company's Board of Directors.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health, based on strong parasiticide trends observed in a recent survey of veterinary clinics. The survey indicated that broad-spectrum parasiticides are performing well, with 64% of clinics prescribing more than the previous year, and Elanco's Quattro and Zenrelia products showing strong, efficacy-driven adoption. This positive outlook for Elanco contrasts with some challenges faced by Zoetis, whose shares are trading near a 52-week low despite appearing undervalued by InvestingPro analysis.
KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends
KeyBanc has reiterated an Overweight rating and a $30.00 price target for Elanco Animal Health (NYSE:ELAN) due to strong parasiticide trends. A recent survey of U.S. veterinary clinics indicated robust demand for broad-spectrum parasiticides, with 64% prescribing more than last year. The analyst also noted competitive pressures on Zoetis’s Simparica Trio are mainly economic, supporting Zoetis's gross-to-net strategy, while Elanco's products like Quattro and Zenrelia are gaining traction.
Elanco Animal Health Eyes Growth, Deleveraging as Quattro and Zenrelia Gain Ground
Elanco Animal Health CEO Jeff Simmons outlined a strategy for growth, innovation, and cash generation at the Bank of America Healthcare Conference. The company aims for mid-single-digit revenue growth, high-single-digit EBITDA growth, and significant deleveraging, with leverage expected to drop to three times by year-end. Key growth drivers include successful product launches like Quattro and Zenrelia, and continued strong performance in its farm animal business.
Elanco (NYSE: ELAN) CFO now holds 158.6535 deferred stock units
Elanco's EVP and CFO, Robert M. VanHimbergen, was granted 8.7877 Deferred Stock Units on September 18, 2026. This award increases his total direct holdings to 158.6535 Deferred Stock Units, each representing the right to receive one share of common stock or its cash equivalent. The units are valued at $22.42 each and settle upon termination of employment or a specified future date as per the Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) CEO adds 126 deferred stock units
Elanco Animal Health Inc. CEO Jeffrey N. Simmons was granted 126.0897 Deferred Stock Units on September 18, 2026, increasing his long-term equity compensation. These units, valued at $22.42 each, represent the right to receive one share of common stock or its cash equivalent upon termination of employment or in a specified future year. Following this award, Simmons directly holds a total of 25,371.5983 Deferred Stock Units.
Elanco Animal Health CEO Jeffrey N. Simmons Reports Acquisition of Deferred Stock Units
Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (NYSE:ELAN), acquired 126.0897 deferred stock units on September 18, 2026, at $22.42 per unit. This transaction, disclosed in a Form 4 filing, increases his direct beneficial ownership to 25,371.5983 units. These deferred stock units will be settled in cash or shares upon employment termination or a specified future year, under the Executive Deferral and Stock Match Plan.
Elanco (NYSE: ELAN) exec adds 65.8756 deferred stock units
Rajeev A. Modi, Executive Vice President at Elanco Animal Health Inc (ELAN), was granted 65.8756 deferred stock units on September 18, 2026, as part of a compensation award. Each unit represents the right to receive one share of common stock or its cash equivalent, settling after employment or in a specified future year under the company's Executive Deferral and Stock Match Plan. Following this transaction, Modi directly holds 9,896.4707 deferred stock units.
Stifel reiterates Elanco Animal Health stock rating on Befrena outlook By Investing.com
Stifel reiterated a Buy rating and $33.00 price target for Elanco Animal Health (NYSE:ELAN), driven by strong adoption expectations for its Befrena product. Despite the stock trading above its fair value according to InvestingPro, the firm anticipates Befrena will significantly contribute to organic growth in 2027 and 2028. This outlook is supported by recent strong Q2 2026 results and a credit rating upgrade from Fitch, reflecting Elanco's strengthened market position and financial stability.
Is Elanco Animal Health (ELAN) Undervalued As Growth Expectations Meet A Recent Pullback?
Elanco Animal Health (ELAN) has garnered attention due to recent share price movements and improving financial figures. Despite a recent pullback, the company's long-term shareholder returns are strong, and it is considered 26% undervalued based on a modeled fair value of $31.21 against its current price of $23.17. Analysts project annual revenue growth of 4.9% and an increase in profit margins from -4.0% to 5.1% over the next three years.
Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2026 financial results on Friday, November 6, 2026. The company will also host a conference call for investors and media on the same day at 8:00 a.m. Eastern Time, with a live webcast and replay available on its investor relations website.
Deferred stock award lifts Elanco Animal Health (NYSE: ELAN) exec's holdings
Elanco Animal Health's EVP, Rajeev A. Modi, received a grant of 60.2829 Deferred Stock Units (DSUs) on September 4, 2026, priced at $24.50 per unit. This award increases his total direct DSU holdings to 9,830.5951 units. These DSUs represent the right to receive one share of Elanco common stock or its cash equivalent, settling after employment termination or in a specified future year under the company's Executive Deferral and Stock Match Plan.
Animal Health Is at the Center of Society's Most Important Trends
Elanco Animal Health, guided by its belief in "Food and Companionship Enriching Life," emphasizes the growing importance of animal health in addressing global trends such as increasing protein consumption, pet integration into families, and sustainable food production. The company's business strategy is deeply integrated with environmental, social, and governance (ESG) priorities, focusing on innovation and access to care for animals, economic value for customers, contributions to society, and fostering a strong internal culture. This approach aims to create meaningful societal value, making animal health an essential industry for a healthier and more sustainable future.
Elanco's CLiK Extra Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Elanco Animal Health has received Emergency Use Authorization (EUA) from the FDA for its CLiK Extra wound spray. This product is intended to prevent New World screwworm infestations in various livestock and wildlife species, particularly on or around wounds. Elanco emphasizes the importance of vigilance and early intervention, offering other authorized products like Negasunt Powder and Tanidil, as well as EPA-registered Catron IV, to combat the critical risk posed by the re-entry of New World screwworm into the U.S.
Elanco (NYSE: ELAN) reports new insider share trade
Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc (NYSE: ELAN), reported an insider share transaction involving 117.9362 deferred stock units at a price of $23.97, totaling approximately $3K. These units represent the right to receive common stock or cash equivalent upon termination of employment or a specified future year, as per the Executive Deferral and Stock Match Plan. Following this transaction, Simmons beneficially owns 25,130.1237 deferred stock units.
Elanco Animal Health CEO Jeffrey N. Simmons Acquires 117.94 Deferred Stock Units
Jeffrey N. Simmons, CEO of Elanco Animal Health Inc., acquired 117.9362 deferred stock units (DSUs) at $23.97 each on August 21, 2026, as reported in an SEC filing. This transaction increases his direct holdings to 25,130.1237 DSUs. These units, which can be converted to common stock or cash, are part of the company's Executive Deferral and Stock Match Plan.
Elanco (NYSE: ELAN) EVP now holds 9,770 deferred units
Elanco Animal Health Inc's Executive Vice President, Rajeev A. Modi, was granted 61.6158 Deferred Stock Units on August 21, 2026, as part of an award. Each unit represents a share of common stock or its cash equivalent, settling after employment or in a specified future year. Following this grant, Modi's total direct holdings of Deferred Stock Units now amount to 9,770.3122 units.
Elanco Animal Health (ELAN) Stock Analysis: Unlocking a 30% Upside Potential with Strong Buy Ratings
Elanco Animal Health (ELAN) is a drug manufacturer for specialty and generic animal health products with a market capitalization of $11.97 billion. Analysts project a significant upside potential of approximately 30.22% with an average target price of $31.21, and the company has received 16 buy ratings and only one hold rating. Despite negative EPS and return on equity, Elanco boasts robust free cash flow and a forward P/E of 18.83, indicating investor confidence in its future earnings potential and strategic growth in the animal health sector.
Elanco director Kurzius buys $935,920 in company stock
Elanco Animal Health Inc. director Lawrence Erik Kurzius purchased 40,000 shares of company stock for approximately $935,920. This insider buy follows positive company news including strong Q2 2026 earnings, an upgrade by Fitch Ratings, and a reiterated Buy rating from Stifel, despite some analysis suggesting the stock might be overvalued.
Elanco Animal Health Director Purchased Shares Worth Over $935K
Lawrence Erik Kurzius, a Director at Elanco Animal Health, recently purchased 40,000 shares of the company's common stock for over $935,000. The shares were bought at a weighted average price of $23.398 each on August 20, 2026. Following this transaction, Kurzius now directly owns 188,647 shares of Elanco Animal Health.
Elanco director Kurzius buys $935,920 in company stock
Lawrence Erik Kurzius, a director at Elanco Animal Health Inc. (NASDAQ:ELAN), purchased 40,000 shares of company stock for approximately $935,920 on August 20, 2026. This transaction increased his direct holdings to 188,647 shares and follows positive news for Elanco, including strong Q2 2026 earnings, an upgrade from Fitch Ratings, and a reiterated Buy rating from Stifel.
Elanco Animal Health (NYSE:ELAN) Director Lawrence Erik Kurzius Purchases 40,000 Shares
Elanco Animal Health (NYSE: ELAN) Director Lawrence Erik Kurzius recently purchased 40,000 shares of the company's stock for $936,000, increasing his direct ownership by 26.91%. This insider buying activity follows strong quarterly results where Elanco beat EPS and revenue expectations. Analysts maintain a "Moderate Buy" rating with a consensus price target of $29.09, reflecting a generally positive outlook for the company.
Elanco (NYSE: ELAN) director buys 40K shares, stake now 188,647
Elanco Animal Health Inc (ELAN) director Lawrence Erik Kurzius purchased 40,000 shares of common stock on August 20, 2026, at a weighted average price of $23.398 per share. This open-market transaction increased his direct holdings to 188,647 shares. The purchase is categorized as a "High Impact" and "Positive Sentiment" filing according to Rhea-AI.
Danske Bank A S Makes New $14.35 Million Investment in Elanco Animal Health Incorporated $ELAN
Danske Bank A S has made a new investment of $14.35 million in Elanco Animal Health Incorporated, acquiring 583,026 shares during the second quarter. This positions Danske Bank A S with approximately 0.12% ownership of the company. The article also details other institutional investments, insider transactions, Elanco's financial performance, and recent analyst ratings.
Elanco Animal Health Inc (ELAN) Shares Fall 3.8% -- What GF Scor
Elanco Animal Health Inc (ELAN) shares fell 3.8% to $23.56, indicating a 41.4% overvaluation according to the GF Value™ of $16.66. Despite an overall GF Score™ of 68/100 and strong momentum, the company faces challenges with financial strength and profitability. Notably, insiders have purchased $1.7 million in shares over the past year, suggesting confidence in its future.
245,707 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Great Lakes Advisors LLC
Great Lakes Advisors LLC has purchased 245,707 shares of Elanco Animal Health Incorporated (NYSE:ELAN) valued at approximately $6.05 million. This acquisition is part of broader institutional interest, with 97.48% of the stock owned by institutional investors. Analysts maintain a "Moderate Buy" rating for Elanco, and the company recently exceeded quarterly earnings expectations, reporting $0.34 EPS on $1.37 billion in revenue.
Attention investors: You may be eligible for a $15 million Elanco Animal Health SEC fair fund payment
Investors who purchased Elanco Animal Health (NYSE: ELAN) common stock between May 9, 2019, and May 6, 2020, may be eligible for a payment from a $15 million SEC fair fund. The fund was established after Elanco paid a civil penalty for failing to disclose that quarter-end incentives to distributors boosted its reported revenue growth. Claims must be filed by September 14, 2026, and payments will be based on recognized losses calculated according to a specific plan of allocation.
Elanco Animal Health (NYSE:ELAN): Is More Momentum Ahead?
Elanco Animal Health (NYSE:ELAN) has shown improved operating results and raised its full-year revenue outlook, strengthening its recovery narrative. The company's future valuation hinges on sustained commercial execution, successful product launches, margin improvement, and financial discipline through portfolio changes. While recent momentum is positive, long-term uncertainties remain, requiring consistent execution to support growth and valuation expectations.
Director's Confidence Visible as Elanco Leader Buys 10,000 Shares
Elanco Animal Health Director Paul Herendeen purchased 10,000 shares of the company's common stock for $236,800, bringing his total direct holdings to 111,687 shares. This transaction, occurring above the market close price, signals strong insider confidence in Elanco's future. The company recently reported a 10% increase in Q2 2026 revenue and raised its full-year guidance, with its stock performing well over the past year.
160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha
First National Bank of Omaha recently acquired 160,631 shares of Elanco Animal Health (NYSE:ELAN) valued at approximately $3.97 million during the second quarter. This purchase contributes to institutional investors collectively owning 97.48% of ELAN's outstanding stock. Elanco exceeded quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $29.09.
Shiv O'neill Purchases 3,998 Shares of Elanco Animal Health (NYSE:ELAN) Stock
Insider Shiv O'neill recently purchased 3,998 shares of Elanco Animal Health (NYSE:ELAN) stock for $94,272.84, increasing direct ownership to 87,832 shares. This transaction follows Elanco's strong Q2 2026 earnings, where EPS and revenue exceeded analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $29.09.
Elanco (NYSE: ELAN) legal chief buys 3,998 company shares
Elanco Animal Health Inc (ELAN) officer Shiv O'Neill, General Counsel and Corporate Secretary, purchased 3,998 shares of common stock on August 18, 2026, at $23.58 per share. This open-market transaction increased O'Neill's direct holdings to 87,832 shares. The purchase was not made under a Rule 10b5-1 trading plan.
S&CO Inc. Buys Shares of 111,284 Elanco Animal Health Incorporated $ELAN
S&CO Inc. recently acquired 111,284 shares of Elanco Animal Health Incorporated (NYSE:ELAN) for approximately $2.74 million, contributing to the 97.48% institutional ownership of the company. Elanco exceeded its Q2 earnings expectations, reporting an adjusted EPS of $0.34 and revenue of $1.37 billion, marking a 10.2% year-over-year increase. Analysts maintain a "Moderate Buy" rating for ELAN with an average price target of $29.09, and recent insider purchases by two directors further indicate confidence in the company's prospects.
Elanco Investors Fail to Revive Sales Misrepresentation Suit
The Seventh Circuit Court of Appeals has ruled against Elanco Animal Health Inc. investors, preventing them from proceeding with claims that the company misrepresented its sales. The court upheld the dismissal of the proposed class action, stating that the investors did not adequately allege fraudulent intent regarding the company's distribution practices. The ruling also touched upon violations of Sections 11 and 12(a) of the Securities Act of 1933, aligning with a majority of appeals courts on the interpretation of stricter federal requirements.
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)
J.P. Morgan analyst Chris Schott maintained a Buy rating on Elanco Animal Health (ELAN) with a consensus price target of $31.11, representing a 35.3% upside. Needham analyst Ami Fadia assigned a Buy rating to ACADIA Pharmaceuticals (ACAD) with a price target of $41.00, implying a 16.0% upside. Both companies are seen favorably within the Healthcare sector by these analysts.
Elanco Animal Health (ELAN) director purchases 5,000 shares of stock
Elanco Animal Health Inc. director Michael J. Harrington purchased 5,000 shares of common stock at $21.82 per share on August 12, 2026, increasing his direct holdings to 131,451 shares. This transaction, categorized as a positive "Filing Impact (Moderate)," was an open market or private transaction and not made under a Rule 10b5-1 trading plan. The purchase totals approximately $109,000.
Elanco Animal Health expands US screwworm response
Elanco Animal Health president and CEO Jeff Simmons discusses the company's efforts to combat the screwworm outbreak in the United States. The discussion took place on 'The Claman Countdown', highlighting Elanco's expanded response to the health issue.
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock
Elanco Animal Health's CFO, Robert Vanhimbergen, purchased 4,200 shares of the company's stock for $96,936, increasing his holdings by 3.15%. This insider buying follows Elanco's strong quarterly results, which exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" rating for ELAN with a consensus price target of $29.09.
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock
Elanco Animal Health (NYSE:ELAN) Director Paul Herendeen recently purchased 10,000 shares of the company's stock for $236,800, increasing his total ownership to 111,687 shares. This insider buying follows Elanco's strong quarterly earnings report, where the company beat estimates with $0.34 EPS and saw revenue increase by 10.2% year-over-year to $1.37 billion. Analysts currently hold a "Moderate Buy" consensus rating for ELAN, with an average price target of $29.09.
Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69
Elanco Animal Health Inc. director Paul Herendeen reported an open-market purchase of 10,000 shares of common stock on August 7, 2026, at a price of $23.685 per share. This transaction increased his direct ownership to 111,687 shares. The Form 4 filing indicates a positive sentiment regarding the insider trade, as it was a purchase not made under a Rule 10b5-1 trading plan.
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN
Bank of America Corp DE significantly increased its stake in Elanco Animal Health Incorporated by 38% in Q1, bringing its total holding to $80.36 million. This comes as Elanco reported strong quarterly earnings, beating analyst expectations, and issued positive full-year EPS guidance. Analysts maintain a "Moderate Buy" rating, and company insiders have also recently purchased shares, indicating confidence in the stock.
Elanco Animal Health Number of Employees 2026 | Employee Count & Headcount Data
Elanco Animal Health (ELAN) had approximately 10,025 employees worldwide as of March 2026, marking a 2.8% growth since 2023. The company is actively hiring, with 772 job postings in 2026, a 40.1% increase from 2025. Its workforce is primarily concentrated in North America, and the average salary globally is $70,973.
Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win?
Elanco Animal Health (ELAN) reported stronger Q2 sales and net income, along with an FDA Emergency Use Authorization for its CLiK Extra screwworm-prevention spray. The company also raised its full-year revenue guidance, positioning it as a key player in addressing the New World screwworm threat. This article examines how these developments may impact Elanco's investment narrative, emphasizing the importance of innovation and new product launches for sustained growth.
elanco animal health inc. Positive Earnings Pre-Announcements
Elanco Animal Health Inc. has pre-announced positive earnings, revising its FY26 estimated revenue range upwards from $5.010-$5.085 billion to $5.090-$5.140 billion. This follows recent news of the company boosting its FY26 outlook and experiencing a rise in Q2 income. The article also provides a timeline of other news related to Elanco, including product approvals and past earnings reports.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health reported strong second-quarter 2026 results, exceeding prior guidance with revenue up 10% to $1.368 billion, driven by new pet-health products like Zenrelia and Credelio Quattro, and growth in U.S. farm animal operations. The company raised its full-year organic constant-currency revenue growth outlook to 6% to 7% and improved its net leverage target. Innovation in both pet and farm animal segments, alongside productivity initiatives, are key drivers for Elanco's sustained growth.
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages
Elanco Animal Health (NYSE:ELAN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $29.09, significantly above its current share price of $22.06. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $0.34 on revenues of $1.37 billion, and provided positive guidance for Q3 and full-year 2026 EPS. Insider purchases by CEO Jeffrey N. Simmons and Rajeev A. Modi, alongside 97.48% institutional ownership, highlight confidence in the stock.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health reported strong Q2 2026 earnings, exceeding guidance with revenue up 10% year-over-year and adjusted EPS increasing 31%. Growth was primarily driven by pet health products like Zenrelia and Credelio Quattro, leading the company to raise its full-year outlook for organic constant-currency revenue growth. Elanco also reduced its net debt and improved its year-end net leverage target.
elanco animal health inc. Positive Earnings Pre-Announcements
Elanco Animal Health Inc. (ELAN) has pre-announced positive earnings for FY26, with an updated estimated range of $5.090-$5.140 Billion, up from $5.010-$5.085 Billion. This follows a recent boost in their FY26 outlook and a 7% stock increase reported on August 5, 2026. The company also announced a rise in Q2 income and USDA approval for a new product.
Elanco Ends Lobbying Relationship With Stumptown Strategies
Elanco Animal Health Inc. has terminated its lobbying contract with Stumptown Strategies LLC, a firm it paid approximately $10,000 per quarter. The company, which had Blair Larkins as its primary lobbyist, has been advocating for the Innovative FEED Act, legislation aimed at reclassifying certain animal feed substances as food additives rather than animal drugs.
